Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

Sol-Gel Technologies Ltd.

Sol-Gel Technologies ( ($SLGL) ) just unveiled an announcement. On November 20, 2025, Sol-Gel Technologies announced its financial results for the ...

Market Cap	$98.62M	P/E Ratio	N/A
52W High	$52.26	52W Low	$4.02
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	-67.7%	52W Position	67.6%
Overall Score	80	Value Score	--
Quality Score	--	Technical Score	80

EPS Current Est	$-0.68	EPS Next Est	$-6.6
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SLGL	$36.65	+2.52%	3.79K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SLGL	$36.65	+2.5%	3.79K
3
4
5
6

SLGL

SLGL

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Sol-Gel Technologies Ltd. Data in Excel

Get Sol-Gel Technologies Ltd. Data in Excel